作者: Hirotsune Itahana , Eisuke Nozawa , Takaho Matsuzawa , Koichiro Harada , Ayako Moritomo
DOI:
关键词:
摘要: It is intended to provide a compound which can be used for preventing and/or treating disease associated with 5HT2B receptor and 5HT7 receptor, particularly irritable bowel syndrome (IBS) migraine. was found that an acylguanidine derivative characterized by having tricyclic structure or pharmaceutically acceptable salt thereof has strong antagonism receptor. In addition, the of invention both receptors showed better pharmacological action compared case where antagonist selective one solely used. From above results, useful